Brief communication

Low variation in initial CD4 cell count in a HIV referral center, in Salvador, Brazil, from 2002 to 2015

Marcela Fonseca Pereira, Estela Luz, Eduardo Martins Netto, Manoel Henrique Fonseca Barbosa, Carlos Brites*

Universidade Federal da Bahia, Faculdade de Medicina, Complexo Hospitalar Professor Edgard Santos, LAPI – Laboratório de Pesquisa em Infectologia, Salvador, BA, Brazil

ARTICLE INFO

Article history:
Received 2 February 2018
Accepted 1 May 2018
Available online 6 June 2018

Keywords:
HIV/AIDS
CD4
Antiretroviral therapy

ABSTRACT

Early initiation of antiretroviral therapy increases the likelihood of effective immune restoration, quality of life, and greater life expectancy for HIV-infected individuals. We evaluated the evolution of mean CD4+ cells count at diagnosis of HIV/AIDS in Salvador, Brazil from 2002 to 2015. We identified HIV/AIDS patients older than 18 years with diagnosis of HIV infection from 2002 to 2015, who had their first laboratory evaluation at Complexo Hospitalar Prof. Edgard Santos, Federal University of Bahia. Initial mean CD4+ cells count and age, over time were evaluated. A total of 1801 patients randomly selected individuals were included in the analysis. Overall mean CD4+ count at diagnosis in the whole period was 279 ± 265, varying from 191 in 2015 to 334 in 2011. There was no improvement in the immunological status at diagnosis from 2002 to 2015. In addition, a higher frequency of CD4+ cells count < 200 cells/mL in the last two years was observed. This suggests that the adopted strategies for early diagnosis of HIV/AIDS in Salvador, Brazil, are still ineffective.

© 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Around 38.6 million people are infected with HIV-1 worldwide. Depletion of CD4+ T cells, especially in lymphoid tissues, is the main consequence of HIV-1 infection, and leads to immunological failure in the absence of effective treatment.1

Successful antiretroviral therapy (ART) makes possible immune restoration, reducing the frequency of hospitalizations and opportunistic infections, and turning HIV/AIDS into a chronic disease. In consequence, treated HIV-infected patients may have a life expectancy similar to that observed for general population. Currently, more than 50% of the deaths in HIV-infected patients receiving effective ART are caused by non-AIDS-related problems.2

Early initiation of treatment (CD4+ cell count ≥ 500 cells/mm³), usually provides conditions to a successful immune restoration. In addition, ART has proven to play a key role in reducing HIV transmission. Late diagnosis

* Corresponding author.
E-mail address: cbrites@gmail.com (C. Brites).

https://doi.org/10.1016/j.bjid.2018.05.005
1413-8670/© 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of HIV infection increases the risk of virus transmission and disease progression to AIDS.\textsuperscript{2,3} However, about 50% of HIV-infected individuals worldwide do not know their status.\textsuperscript{6} In Brazil, since 2013 all HIV-infected individuals are eligible to start ART, irrespective of CD4+ cells count.\textsuperscript{7}

The Brazilian Ministry of Health reported around 11,700 HIV in the study period, and the proportion of patients with a CD4+ cells count ≤ 350 cells/mm\textsuperscript{3} ("late presenters") varied between 38% (2015) and 72% (2009).\textsuperscript{8} This study aims to evaluate the changes of mean initial CD4+ cells count for patients with a diagnosis of HIV/AIDS in Salvador, Brazil from 2002 to 2012.

We included HIV/AIDS outpatients older than 18 years who had their first laboratory evaluation at the Laboratório de Pesquisa em Infectologia (LAPI), located at Complexo Hospitalar Prof. Edgard Santos, Federal University of Bahia (CHUPES), from 2002 to 2015. The data was randomly extracted from National Database for Laboratory in HIV/AIDS (SISCEL) and electronic medical records. We collected information on the first results of CD4+ cells count and viral load for patients diagnosed in the study period. Using the official estimates for new HIV cases in the study period we selected a sample of 1801 patients (a minimum of 100 patients/year) by a computer-generated list. To calculate the sample size, we used the minimal and maximal estimates for late presentation of patients in the period (40% and 72%, respectively). We added a 20% excess to account for potential problems in retrieving information. The final sample (1801 patients) provided 99.99% confidence interval.

We estimated frequencies, means, standard deviations, medians, and quartiles for the main variables using SPSS Version 20 software. Stratified analyses were performed by sex, year of diagnosis, and CD4+ cells count categories. For analysis purposes CD4+ cells count was also stratified in four distinct categories: (1) < 200 cells per mm\textsuperscript{3}; (2) from 201 to 350 cells per mm\textsuperscript{3}; (3) from 351 to 500 cells per mm\textsuperscript{3}; (4) > 500 cells per mm\textsuperscript{3}. An initial CD4+ cells count ≤ 350 cells/mm\textsuperscript{3} was considered as late presentation for health care.

A total of 1801 patients with HIV/AIDS diagnosis from 2002 to 2015 was included, 63.4% were male. Mean age at diagnosis was 37.3 years ± 10.3 (18.1 to 83.5 years). The mean age at diagnosis was similar overtime and oscillated from 34.4 ± 9.4 in 2006 to 38.9 ± 10.5 in 2013. Most (69.4%) patients lived in Salvador, 27.9% in other cities in Bahia, and 2.7% lived in other Brazilian states.

The overall CD4+ cell count mean at diagnosis in the whole period was 279 ± 265. The plasma viral load at diagnosis oscillated from 83 copies/mL to more than 500,000 copies/mL while the mean CD4+ cell count ranged from 191 in 2015 to 334 in 2011. Table 1 shows the mean CD4+ cell count per year. The stratified analysis of mean CD4+ cell count showed a higher proportion of patients with a mean CD4+ cell count lower than 350 cells/mm\textsuperscript{3} in the study period. It also showed a lower mean CD4+ cell count (< 200 cells/mm\textsuperscript{3}) in 2014 and 2015, in comparison to previous years. Fig. 1 shows the variation of mean CD4+ cell count over time.

In the present work, late presentation to health care was observed for the duration of the study, with a high proportion of patients with a CD4 count below 300 cells/mm\textsuperscript{3} at first visit. In addition, the mean age at diagnosis did not present significant variation. Most individuals lived in Salvador and were expected to have easier access to health care than those living in smaller cities.

According to the Brazilian Ministry of Health, in 2015 the proportion of individuals with first CD4+ cell count lower than 200 cells/mm\textsuperscript{3} had a tendency to decrease, from 31% in 2009 to 25% in 2015.\textsuperscript{3} In contrast, our results show increase in the proportion of individuals diagnosed with CD4+ cell count lower than 200 cells/mm\textsuperscript{3} in the years 2014 and 2015, in Bahia. Moreover, we did not observe any improvement in the proportion of early HIV diagnosis in the last 13 years.

A similar epidemiological picture is observed in other studies. Souza Jr et al. detected a high prevalence of HIV/AIDS diagnosis performed at an advanced stage of infection, with a consequent delay in ART introduction. Other studies carried out in Belo Horizonte, São Paulo, and Rio de Janeiro have shown that the proportion of late presentation of HIV-infected patients to health care is still high in these Brazilian states.\textsuperscript{9-12}

Studies carried out in other countries have shown distinct results.\textsuperscript{6,13-17} Lesko (2013) observed that the CD4 cell count at the time of presentation for health care services had a non-significant increase in developed countries from 1992 to 2011, while Kiertiburanakul (2014) concluded that CD4 cell count at the time of ART initiation increased significantly in some Asian countries from 2007 to 2011, and that there was a significant reduction in delay to start treatment, although the late presentation rate remained elevated. The increase in frequency of early diagnosis in Asian countries was attributed to changes in health practices, updating WHO recommendations (World Health Organization) and to the expansion in availability of HIV testing during prenatal care. In addition, Ransome (2015) showed a decline in late presentation rates in New York, especially among men, which was associated to increased coverage of HIV testing from 2003 to 2010.\textsuperscript{18}

Our results suggest that late-presentation is still a main problem for AIDS patients in Salvador, Brazil. We detected a concerning low mean initial CD4 cell count in the last two years. This suggests that the currently adopted strategies to increase early diagnosis of HIV/AIDS in Salvador, Brazil, are still inefficient. A wider HIV screening of people at risk and of those that present acute infection symptoms should be considered. The sample obtained from one single site is the main

#### Table 1 — Mean CD4+ cells count (per mm\textsuperscript{3}) at first medical evaluation according to the year of diagnosis.

| Year | n  | Mean ± SD (95% CI) |
|------|----|------------------|
| 2002 | 135| 258 ± 216 (221–295) |
| 2003 | 118| 254 ± 234 (212–297) |
| 2004 | 140| 358 ± 285 (311–406) |
| 2005 | 133| 285 ± 223 (247–324) |
| 2006 | 104| 310 ± 287 (254–363) |
| 2007 | 125| 269 ± 238 (227–311) |
| 2008 | 148| 246 ± 217 (211–283) |
| 2009 | 158| 283 ± 299 (236–330) |
| 2010 | 146| 241 ± 256 (199–283) |
| 2011 | 139| 334 ± 287 (286–383) |
| 2012 | 144| 302 ± 259 (259–344) |
| 2013 | 105| 359 ± 385 (285–434) |
| 2014 | 107| 200 ± 216 (159–241) |
| 2015 | 102| 191 ± 214 (149–233) |
limitation of our work, which limits the external validity of our findings. However, LAPI performs CD4/CD8 tests and viral load for about 40% of HIV population in Bahia, which increases the overall relevance of our sample. Larger studies are necessary to confirm our results and to define the real situation of HIV diagnosis in Brazil.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368:489–504.
2. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.
3. Komninakis SV, Mota ML, Hunter JR, Diaz RS. Late presentation HIV/AIDS is still a challenge in Brazil and worldwide. AIDS Res Hum Retroviruses. 2018;34:129–31.
4. Owen SM. Testing for acute HIV infection: implications for treatment as prevention. Curr Opin HIV AIDS. 2012;7:125–30.
5. Piñera A, Sierra-Madero J, Cahn P, et al. The HIV care continuum in Latin America: challenges and opportunities. Lancet Infect Dis. 2015;15:833–9.
6. Organização Mundial de Saúde. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2014.
7. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, AIDS e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para adultos vivendo com HIV/AIDS. Brasília: Ministério da Saúde; 2013.
8. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, AIDS e Hepatites Virais. Boletim epidemiológico HIV AIDS. Brasília: Ministério da Saúde; 2015.
9. Souza Jr PR, Szwarcwald CL, Castilho EA. Delay in introducing antiretroviral therapy in patients infected by HIV in Brazil, 2003–2006. Clinics. 2007;62:579–84.
10. Valentini MB, Toledo ML, Fonseca MO, et al. Evaluation of late presentation for HIV treatment in a reference center in Belo Horizonte, Southeastern Brazil, from 2008 to 2010. Braz J Infect Dis. 2015;19:253–62.
11. Moreira R, Luz PM, Struchiner CJ, et al. Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr. 2011;57 Suppl. 3:S171–8.
12. Khoury Z, Silva RS, Villela W. Factors associated with a delay in seeking HIV/AIDS treatment in Sao Paulo, Brazil. AIDS Behav. 2015;19:679–83.
13. Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and metaregression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992–2011. Clin Infect Dis. 2013;57:1027–37.
14. Kiertiburanakul S, Boettiger D, Lee MP, et al. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. J Int AIDS Soc. 2014;17:18804.
15. Kittner JM, von Bialy L, Wiltink J, et al. Lack of awareness in both patients and physicians contributes to a high rate of late presentation in a South West German HIV patient cohort. Infection. 2015;43:299–305.
16. d’Arminio Monforte A, Cozzi-Lepri A, Girardi E, et al. Late presenters in new HIV diagnoses from an Italian cohort of HIV infected patients: prevalence and clinical outcome. Antivirals Ther. 2011;16:1103–12.
17. Zoufaly A, an der Heiden M, Marcus U, et al. Late presentation for HIV diagnosis and care in Germany. HIV Med. 2012;13:172–81.
18. Ransome Y, Terzian A, Addison D, et al. Expanded HIV testing coverage is associated with decreases in late HIV diagnoses. AIDS. 2015;29:1369–78.